Antibody Discovery

San Diego, CA, United States

Antibody Discovery

San Diego, CA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | February 22, 2017
Site: www.accesswire.com

Developing Novel Therapeutics for Difficult-To-Treat Cancers with its Antibody Discovery Platform NEW YORK, NY / ACCESSWIRE / February 22, 2017 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of BioInvent (Stockholm: BINV.ST), a biopharmaceutical company developing novel therapeutics for difficult-to-treat cancers. The Company utilizes its antibody discovery platform n-CoDeR/F.I.R.S.T to develop oncology candidates with novel mechanisms of action. The Company's lead clinical candidate, BI-1206, is an antibody that targets FcgRIIB, also known as CD32b. CD32b is expressed in a number of B-cell malignancies and is associated with the development of rituximab resistance. BI-1206 is currently being evaluated in a Phase I/IIa study as both a single-agent, and in combination with rituximab in patients who have relapsed/refractory non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) and express CD32b. BioInvent's second asset TB-403 is being evaluated in a Phase I/II study for patients who have relapsed/refractory medulloblastoma, a rare form of brain cancer that primarily affects children. TB-403 is an antibody that targets placental growth factor (PlGF), which has the downstream ability to inhibit neuropilin 1 (Nrp1) mediated signaling. Nrp1 is highly expressed in patients with medulloblastoma, and higher expression is correlated with a poor prognosis. The Company's n-CoDeR library contains more than 30 billion fully human antibodies. The F.I.R.S.T screening tool is designed to find antibodies from this library that have activity against cancer-associated targets, while having minimal impact on normal tissues. The most potent antibodies are advanced into preclinical studies. BioInvent has agreements with leading pharmaceutical companies to use its n-CoDeR and F.I.R.S.T platforms. There are 5 ongoing Phase I studies and 4 ongoing preclinical studies with candidates originating from BioInvent's antibody discovery platform. The advancement of partnered clinical candidates would provide considerable milestone and royalty payments to BioInvent. In a 43 page Initiation Report LifeSci Capital explains the preclinical and clinical data supporting BI-1206, TB-403, and other clinical candidates. We outline the market opportunity for each indication and discuss the landscape of approved agents and those in development. Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on BioInvent as developments occur. The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego. LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.


News Article | December 8, 2016
Site: www.businesswire.com

AUCKLAND, New Zealand--(BUSINESS WIRE)--A whitepaper released today by bioinformatics technology company Biomatters examines the critical role big data will play in enabling scientists to discover life saving biologic drugs of the future. The whitepaper discusses how technology innovations such as high-throughput DNA sequencing have created a big data challenge and opportunity for enterprises involved in monoclonal antibody (mAb) therapeutic development. Today, biopharmaceutical enterprises are generating huge volumes of data throughout the discovery, pre-clinical and clinical stages of development of new antibody based therapeutics, but face multiple challenges in leveraging that data, including data accuracy, data completeness, difficulties combining data that comes from different sources and complexity of implementing data analytics. Titled Accelerated Precision Antibody Discovery, the whitepaper explores how many of the current challenges in developing mAb therapeutics can effectively be addressed through the provision of a fully managed data platform in a secure cloud computing infrastructure. “Employing comprehensive cloud solutions and leveraging insights from cloud-based analytics in biologics research and development is still in its infancy, but will become an increasing source of competitive advantage for biopharma organizations that adopt this new paradigm early,” said whitepaper author and Biomatters President Brett Ammundsen, PhD. “Biopharma is one of the most information-intensive industries, and has much to gain from implementing systems that facilitate the flow of information across different phases of the drug development process. Cloud technologies now offer enterprises unprecedented opportunities to properly address complex data sets and make better, data driven decisions that, ultimately, save lives,” Dr Ammundsen said. Biomatters (www.biomatters.com) creates technology solutions that solve common bioinformatics problems. Headquartered in New Zealand with offices in the US and Europe and users in more than 100 countries, Biomatters has developed Geneious Biologics, a next generation cloud solution for commercial enterprises, to support their discovery and development of biologic therapeutics.


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock, a biotechnology company focused on discovering and developing drugs that selectively target supracellular activation of growth factors in the disease microenvironment, today announced that Gregory Carven, PhD, the company’s Vice President of Antibody Discovery and Protein Sciences, has received the “Inventor of the Year” award by the national Intellectual Property Owners (IPO) Foundation. The Inventor of the Year award recognizes the world’s most outstanding recent inventors whose creations have made a significant impact on the economy and quality of life across all industries. In receiving the 2016 IPO Foundation’s Inventor of the Year award, Dr. Carven was honored for his work on the invention of pembrolizumab (Keytruda®) while he was at Merck and Company. Dr. Carven was recognized for the award along with fellow Keytruda inventors, Hans van Eenennaam and John Dulos, both of whom now work for Aduro Biotech Europe. Keytruda is a life-saving cancer immunotherapy which works by blocking the programmed cell death protein 1 (PD-1) pathway expressed on T-Cells, a type of white blood cells in the immune system. "We congratulate Greg for being recognized as Inventor of the Year, which reflects his talents and passion for discovering innovative medicines that make an impact for patients,” said Nagesh Mahanthappa, PhD, President and Chief Executive Officer of Scholar Rock. “We see Greg’s dedication to drug discovery innovation every day in his R&D work at Scholar Rock, and we are proud to have such an outstanding scientist and innovator on our leadership team.” About Scholar Rock Scholar Rock is a biotechnology company focused on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The Company’s initial proprietary and partnered drug discovery programs target specific growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology and autoimmune diseases. Scholar Rock was founded upon discoveries made by its scientific founders, Professors Timothy Springer, PhD, and Leonard Zon, MD, of Boston Children's Hospital and Harvard Medical School, related to the molecular mechanisms of supracellular activation. The company is backed by leading investors, including Polaris Partners, Timothy Springer, ARCH Venture Partners, Fidelity Investments, EcoR1 Capital, The Kraft Group, and Cormorant Asset Management.


Chronopoulou E.,Antibody Discovery | Uribe-Benninghoff A.,Antibody Discovery | Corbett C.R.,National Diagnostics | Berry J.D.,Antibody Discovery | Berry J.D.,University of Manitoba
Methods in Molecular Biology | Year: 2014

Monoclonal antibodies (mAbs) have proven to be instrumental in the advancement of research, diagnostic, industrial vaccine, and therapeutic applications. The use of mAbs in laboratory protocols has been growing in an exponential fashion for the last four decades. Described herein are methods for the development of highly specific mAbs through traditional hybridoma fusion. For ultimate success, a series of simultaneously initiated protocols are to be undertaken with careful attention to cell health of both the myeloma fusion partner and immune splenocytes. Coordination and attention to detail will enable a researcher with basic tissue culture skills to generate mAbs from immunized rodents to a variety of antigens (including proteins, carbohydrates, DNA, and haptens) (see Note 1). Furthermore, in vivo and in vitro methods used for antigen sensitization of splenocytes prior to somatic fusion are described herein. © 2014 Springer Science+Business Media, New York.


Uribe-Benninghoff A.,Antibody Discovery | Cabral T.,National Diagnostics | Chronopoulou E.,Antibody Discovery | Berry J.D.,Antibody Discovery | And 2 more authors.
Methods in Molecular Biology | Year: 2014

Described herein are methods for the successful screening of monoclonal antibodies (mAbs) of the desired specificities via high-throughput (HTP) homogeneous assay and flow cytometry. We present a combination of screening techniques that allow the scientist to efficiently eliminate nontarget-specific antibody as soon as possible. This compilation of protocols will enable researchers with basic immunology skills to make decisions regarding the design of screening algorithms for the generation of mAbs. Although we have provided an informative overview of both HTP homogeneous assay and flow cytometry, it is imperative for the beginner to acquire fundamental knowledge on how both of these technologies work so as to use these screening strategies effectively. © 2014 Springer Science+Business Media, New York.


PubMed | Antibody Discovery
Type: | Journal: Methods in molecular biology (Clifton, N.J.) | Year: 2014

Monoclonal antibodies (mAbs) have proven to be instrumental in the advancement of research, diagnostic, industrial vaccine, and therapeutic applications. The use of mAbs in laboratory protocols has been growing in an exponential fashion for the last four decades. Described herein are methods for the development of highly specific mAbs through traditional hybridoma fusion. For ultimate success, a series of simultaneously initiated protocols are to be undertaken with careful attention to cell health of both the myeloma fusion partner and immune splenocytes. Coordination and attention to detail will enable a researcher with basic tissue culture skills to generate mAbs from immunized rodents to a variety of antigens (including proteins, carbohydrates, DNA, and haptens) (see Note 1). Furthermore, in vivo and in vitro methods used for antigen sensitization of splenocytes prior to somatic fusion are described herein.


PubMed | Antibody Discovery
Type: | Journal: Methods in molecular biology (Clifton, N.J.) | Year: 2014

Described herein are methods for the successful screening of monoclonal antibodies (mAbs) of the desired specificities via high-throughput (HTP) homogeneous assay and flow cytometry. We present a combination of screening techniques that allow the scientist to efficiently eliminate nontarget-specific antibody as soon as possible. This compilation of protocols will enable researchers with basic immunology skills to make decisions regarding the design of screening algorithms for the generation of mAbs. Although we have provided an informative overview of both HTP homogeneous assay and flow cytometry, it is imperative for the beginner to acquire fundamental knowledge on how both of these technologies work so as to use these screening strategies effectively.

Loading Antibody Discovery collaborators
Loading Antibody Discovery collaborators